The chest clinic gave me five days and said stop. No taper. Is that the review you would sign?
One 5 mg chip, five doors, one receptor
Prednisolone does not treat a single disease name. It turns down a shared inflammatory script.
The same glucocorticoid receptor sits in lung, synovium, bowel, skin, and marrow. Bind it, rewrite gene expression, and inflammatory mediators fall. That is why one prednisolone 5 mg tablet appears on so many kardexes. It is also why the same tablet can thin bone and blunt infection defence. Non-selective is the point, not a surprise.
I refuse the sentence 'prednisolone treats everything'. It treats over-active immunity and swelling. It does not treat infection, mechanical back pain, or tiredness with no inflammatory diagnosis. If the working diagnosis is fuzzy, a 5 mg chip is not a diagnostic reagent. It will make the patient feel different and leave you less sure what you treated.
Receptor detail and labelled strengths live on the prednisolone 5 mg medicine note. This page is a set of ward reviews: where the evidence is thick, where the chip is only a bridge, and where the file is too soft to justify months.
Chest: the burst file is the one I trust
Acute asthma that has broken through inhalers still earns an oral glucocorticoid burst. Relapse and admission fall when the course is real and short. Typical adult bursts sit far above a single 5 mg tablet - often 40-50 mg prednisolone daily for about five days - then stop. The 5 mg chip is the counting unit, not the burst dose. I write that in the margin so nobody thinks '5 mg reviews' means a 5 mg asthma course.
COPD exacerbations have a cleaner duration trial than most steroid questions. REDUCE (Leuppi, JAMA 2013) compared 40 mg prednisone daily for 5 versus 14 days in 314 emergency patients, mostly admitted, no asthma history. Five days was noninferior for time to next exacerbation within 180 days. Cumulative exposure dropped hard (about 379 mg versus 793 mg). Extra days did not buy a quieter winter. I file that as a duration hold, not as a licence to skip antibiotics or inhalers.
Paediatric croup can answer to a single dexamethasone dose, which is a cousin, not a 5 mg prednisolone story. Allergic airway oedema and some eosinophilic chest diseases still use short systemic courses. The shared review: name a stop date before the first chip. A burst that quietly becomes a month is no longer the chest file I signed.
Rheumatology: powerful this month, the wrong landlord next year
Vasculitis, lupus with organ threat, polymyalgia, and a rheumatoid flare can need glucocorticoids the way a fire needs a blanket. The evidence for rapid control is old and still solid. The evidence for staying on a meaningful prednisolone 5 mg-multiple indefinitely, without a steroid-sparing plan, is a toxicity file wearing a disease badge.
Modern rheumatology uses the tablet as a bridge: knock the flare down, start a DMARD or biologic, then walk the steroid off. If someone is still on more than physiologic replacement at a year with no exit, I do not congratulate the joint count. I ask which sparing agent failed or was never tried. Feeling well on 10 or 15 mg is not a review of success. It is a review of postponed bone and infection cost.
Polymyalgia is the exception people quote. Some patients need a slow, disease-led taper that lasts months. That is still a planned descent, not an open bottle. Peer-line it against the two-week axis rule so the disease taper and the adrenal taper are not treated as one scribble.
Gut, skin, and blood: same chip, different stop stories
Ulcerative colitis and Crohn flares still see oral prednisolone when 5-ASA and the acute work-up say inflammation, not infection. The review I want on the chart is the exit: thiopurine, biologic, diet trial, surgery talk - something that is not a 5 mg tablet forever. Steroid-dependent IBD is a failure of the plan, not a personality of the drug.
Dermatology uses short courses for severe contact dermatitis, bullous disease, and some vasculitic rashes. Topical steroids should do the chronic work. If a skin patient is swallowing prednisolone 5 mg for months because 'the cream failed', I look at the cream, the diagnosis, and the infection risk before I look at a higher chip.
Autoimmune haemolysis and ITP can need high-dose glucocorticoids in the first days. Those files are organ-saving. They are also the files where infection and bone start accruing the moment the crisis ends and nobody books the taper. Haematology knows this. The margin still has to say it, because the patient only hears 'the numbers went up'.
The 5 mg row on the equivalence card
Wards swap steroids. Getting the row wrong is an avoidable dose error.
| Steroid | Equivalent dose | Punch vs hydrocortisone | Salt | Window |
|---|---|---|---|---|
| Hydrocortisone | 20 mg | 1 (reference) | High | Short, 8-12 h |
| Prednisolone | 5 mg | About 4x | Low | Intermediate, 12-36 h |
| Prednisone (US card) | 5 mg if liver works | About 4x | Low | Intermediate, 12-36 h |
| Methylprednisolone | 4 mg | About 5x | Minimal | Intermediate, 12-36 h |
| Dexamethasone | 0.75 mg | About 25-30x | None | Long, 36-72 h |
Anti-inflammatory equivalence, the card I keep: hydrocortisone 20 mg ≈ prednisolone 5 mg ≈ methylprednisolone 4 mg ≈ dexamethasone 0.75 mg. Salt effect falls as you move down that list. Duration lengthens. Hydrocortisone is the replacement steroid. Prednisolone 5 mg is the outpatient workhorse. Dexamethasone is the long, salt-silent hammer.
Prednisone is printed as 5 mg on many US cards beside prednisolone 5 mg. Read that as a healthy-liver US habit, not as a worldwide law. UK charts often omit prednisone. A Japanese or EU blister may not be the twin you pictured. Liver failure belongs on prednisolone, not on a prodrug you hope the hepatocyte will finish. I repeat this on a uses page because the conversion error happens on the ward, not in a history seminar.
Do not convert by counting tablets. A 5 mg prednisolone chip is not a 5 mg dexamethasone chip. It is not a 5 mg methylprednisolone chip. Write the name, then the milligram, then the days. MedlinePlus on prednisolone is a plain patient page. It will not do the country conversion for you.
When a five-day review quietly becomes a year
| Review axis | Burst (days to ~2 weeks) | Long haul (months to years) |
|---|---|---|
| Typical ward | Asthma or COPD flare, croup, acute allergy, gout | Autoimmune maintenance, transplant, steroid-dependent IBD |
| What patients notice | Sleep, hunger, mood, a sugar bump | Bone, infection, eyes, weight, skin |
| Reversibility | Mostly yes | Bone and cataracts may keep a scar |
| HPA axis | Usually still alive; many bursts just stop | Assume hush; taper |
| Evidence temperature | Thick for defined flares | Control is real; maintenance cost is the story |
Risk flips with the calendar. A five-day burst buys insomnia, appetite, mood swing, a glucose bump. Acceptable when an airway or a joint is on fire. Mostly reversible. A year of prednisolone 5 mg-multiples buys osteoporosis, cataracts, diabetes, hypertension, myopathy, thin skin, a Cushing face, infection, and an HPA axis that will not restart the morning you feel well.
Benefit plateaus. Harm accumulates. That sentence is the whole long-term review. I do not need a new trial every decade to keep writing it. The patients who 'feel amazing' in week two are the ones who later fight the taper. Euphoria is a glucocorticoid effect, not a green light.
If the disease is chronic, the review I want is the sparing agent, not a prettier 5 mg schedule. If the disease was a flare, the review I want is the stop date. Mixing those two files is how a chest burst becomes an unmarked maintenance dose.
Soft indications: the reviews I will not inflate
Sepsis is not a prednisolone 5 mg story. Some shock protocols use hydrocortisone in selected patients. That is a different molecule, a different dose, a different room. Chronic back pain and unexplained fatigue do not have a glucocorticoid evidence file that survives a hard read. Cheap and familiar is not a trial.
I ask two questions before I let a soft indication stay on the kardex. What inflammatory diagnosis is named? What is the stop date? If either answer is a shrug, the review is negative. Infection must be off the table first. A worm, a hidden abscess, or tuberculosis will not thank you for a 5 mg immunosuppressive chip.
Cross-check the parasite question on its own page if the eosinophil count or the travel history is the real story - not here. This file stays on prednisolone. Helena will not stretch a flare trial into a lifestyle tablet because a reader slept well on day three.
Three harms that sit on every long review
Infection: fever can be quieter, wounds slower, latent tuberculosis and some opportunistic bugs more willing. Live vaccines are a hold on meaningful doses. I do not wait for a dramatic pneumonia before I write this in the margin. The risk is the point of the drug.
Bone: loss starts early and is silent. Calcium and vitamin D are the cheap first line, not a complete plan. DEXA belongs on courses that stretch into months. Bisphosphonates enter when fracture risk is high, not when the first vertebral crush has already announced itself. A prednisolone 5 mg tablet taken for years is not 'too small to matter' to trabecular bone.
HPA axis: past about two weeks of more-than-replacement glucocorticoid, assume the adrenals have gone quiet. That is why a long review must end in a taper, not in a bin. The history of the 5 mg tablet explains the power. This page ranks the uses. The next page is the stop rule.
How I file a use before I sign the margin
Defined inflammatory flare, a stop date inside about two weeks, infection considered: the 5 mg chip (in the counted daily dose) earns a yes. Chronic autoimmune disease with a sparing plan and a descent: a qualified yes. Open-ended symptoms, no diagnosis, no exit: a no. I do not need a fourth category.
Country bottles still confuse reviews. A US prednisone burst and a UK prednisolone burst may be intended as the same anti-inflammatory idea. They are not automatically the same tablet in a suitcase. Write the INN that was dispensed. Then review that.
Bring the plan to your own clinician before you add or stretch a chip. This desk files teaching notes. It does not write your burst. If the course has already run long, leave this page and open the taper file. Feeling well is not a review of safety.
Reader mail
Reader questions on this article
Answered by Dr. Helena Vasquez, PharmD · Clinical pharmacology & drug safety
Ward questions after the reviews. Named, then filed. Not a personal burst plan.
For a first, short airway burst - about five days, even at 40 mg - many desks stop without a taper. The axis is usually still awake. REDUCE supports five days over fourteen in COPD exacerbations. The hold changes if you have had repeated courses, look Cushingoid, or the calendar already passed about two weeks. I can sign the pattern. I cannot sign your chart from mail.
Why move me off prednisolone 5 mg when my joints finally behave?
Joints behaving is the bridge working. It is not a 10-year landlord. Bone, infection, glucose, and the HPA axis keep the meter running after the pain score has plateaued. The review I want next is a DMARD or biologic, then a descent. Staying because 'it works' is how a flare drug becomes the disease. Ask your rheumatology desk for the sparing name, not for a prettier 5 mg habit.
Hospital used dexamethasone. Home script says prednisolone 5 mg. Did they downgrade me?
They changed potency and duration, not your worth. Dexamethasone is many times stronger milligram-for-milligram and lasts longer. A 5 mg prednisolone tablet is a different row on the card. Convert by equivalence, not by tablet count. If the hospital did not write the conversion, ask before you guess. I will not invent your milligram from a discharge photo.
Does a burst cure an asthma attack or only hide it?
For that episode, a burst can break the inflammatory wave so the attack actually ends. That is as close to 'cure this event' as a glucocorticoid gets. It does not rewrite the airway for life. Inhaled steroids and the trigger list do the next year. Autoimmune disease is the other file: suppress while you take it, disease still underneath. Do not import the asthma-burst feeling into lupus maintenance.
I felt electric on day three - sleep optional, mood high. Can I keep a 5 mg tablet for that?
That lift is a known glucocorticoid effect. It is also the hook. The same broad receptor later taxes bone, glucose, and your own cortisol. Pleasant week two is not a safety signal. I file mood elevation under adverse effect, not under indication. If energy was the goal, this is the wrong drug class.
Which uses have reviews so thin I should push back?
Chronic back pain, unexplained fatigue, 'boost my immunity' (it does the opposite), and open-ended 'inflammation' with no diagnosis. Sepsis protocols that people quote are usually hydrocortisone in shock, not a prednisolone 5 mg outpatient chip. Ask for the trial, the stop date, and the infection screen. A shrug is a no.
How can one 5 mg idea cover asthma, colitis, and lupus?
Shared upstream script: over-active immunity in different rooms. Prednisolone binds one receptor family and turns inflammatory genes down body-wide. Four diseases, one process. The same breadth is why infection and bone sit on every long review. Breadth is the mechanism, not a miracle.
Is a US prednisone burst the same review as a UK prednisolone burst?
Same idea on a healthy liver: an oral intermediate glucocorticoid for a defined flare. Not the same bottle law. UK desks write prednisolone. US desks often write prednisone. Do not match suitcase chips by the 5 mg stamp alone. Review the INN that was dispensed, then the days.
Where do infection and bone belong if my burst was only a week?
A clean week is mostly a glucose-and-sleep story. Infection and bone become the lead review when bursts repeat or the calendar stretches past about two weeks. If you already live on prednisolone 5 mg-multiples, those two harms are current, not theoretical. The taper file is the next read, not another uses paragraph.
General education from a clinician, not personal medical advice. Bring your own history to your own prescriber.
Last Updated